Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced positive results from the part C portion of its phase 1 clinical trial of IMU-856 in patients with celiac disease.
